Novel drug classes with antibacterial activity

Antimicrobial resistance (AMR), particularly multidrug-resistant (MDR) infections of animals and humans, continues to pose significant challenges to public health care systems and global economies. Therefore, there is an urgent need to develop new, broad-spectrum antimicrobials with novel chemistry and mechanisms of action, preventing further cross-resistance to existing drug classes. This project will continue the development of Neoculi’s lead antibacterial candidate NCL195 and improved analogues with the goal of developing a novel, orally delivered medicine for dogs for the treatment of resistant Staphylococcus pseudintermedius and Streptococcus canis infections. As NCL195 has antifungal activity, there is also potential it could be used in the treatment of generalized Malassezia pachydermatis infection which will be the subject of a separate project proposal.